TY - JOUR
KW - Digestive system cancers
KW - Drug screening
KW - organoids
KW - Personalized medicine
KW - precision oncology
KW - Tumor Microenvironment
AU - Yufei Wang
AU - Limin Zhang
AU - Louis Zizhao Wang
AU - Yang Cao
AU - Lulu Huang
AU - Gautam Sethi
AU - Xiaoguang Chen
AU - Lingzhi Wang
AU - Boon-Cher Goh
AB - Digestive system cancers—including gastric, liver, colorectal, esophageal, and pancreatic malignancies—remain leading causes of cancer death, with treatment resistance posing major challenges in advanced disease. Patient-derived cancer organoids (PDCOs), 3D mini-tumors grown from patient biopsies, have revolutionized personalized oncology by faithfully replicating tumor biology and enabling predictive drug testing for chemotherapy, radiotherapy, targeted therapy, and immunotherapy. While demonstrating good predictive accuracy, current limitations include incomplete tumor microenvironments, variable establishment rates, and lengthy processing times. Emerging technologies like AI, organ-on-chip systems, and 3D bioprinting are addressing these challenges, while clinical trials explore applications in neoadjuvant therapy and real-time treatment guidance. This Review highlights key advances in PDCO technology and its transformative potential for treatment decision-making in digestive system cancers, bridging laboratory research with clinical care to enable truly personalized therapeutic strategies tailored to individual tumor biology.
BT - Molecular Cancer
DA - 2025-08-25
DO - 10.1186/s12943-025-02429-0
IS - 1
N2 - Digestive system cancers—including gastric, liver, colorectal, esophageal, and pancreatic malignancies—remain leading causes of cancer death, with treatment resistance posing major challenges in advanced disease. Patient-derived cancer organoids (PDCOs), 3D mini-tumors grown from patient biopsies, have revolutionized personalized oncology by faithfully replicating tumor biology and enabling predictive drug testing for chemotherapy, radiotherapy, targeted therapy, and immunotherapy. While demonstrating good predictive accuracy, current limitations include incomplete tumor microenvironments, variable establishment rates, and lengthy processing times. Emerging technologies like AI, organ-on-chip systems, and 3D bioprinting are addressing these challenges, while clinical trials explore applications in neoadjuvant therapy and real-time treatment guidance. This Review highlights key advances in PDCO technology and its transformative potential for treatment decision-making in digestive system cancers, bridging laboratory research with clinical care to enable truly personalized therapeutic strategies tailored to individual tumor biology.
PY - 2025
EP - 222
ST - The application of organoids in treatment decision-making for digestive system cancers
T2 - Molecular Cancer
TI - The application of organoids in treatment decision-making for digestive system cancers: progress and challenges
UR - https://doi.org/10.1186/s12943-025-02429-0
VL - 24
Y2 - 2025-08-25
SN - 1476-4598
ER -